Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90 (HSP-HEMATO)

University Hospital Center (CHU) Dijon Bourgogne

Status: Unknown

Conditions: Acute T Lymphoblastic Leukemia (T-ALL); Acute B Lymphoblastic Leukemia (B-ALL)

Treatments: Drug: injection of BEP 800; Other: Control

Study type: Observational

Funder types: Other

Identifiers

NCT04437420

GIRODON Collection 2020

Details and patient eligibility

About

NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).

Enrollment: 44 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.

Exclusion criteria

• Patient over 80 years of age

Trial design

44 participants in 2 patient groups

T-ALL

Treatment:

Other: Control

Drug: injection of BEP 800

B-ALL

Treatment:

Other: Control

Drug: injection of BEP 800